DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actoplus MET (Pioglitazone Hydrochloride / Metformin Hydrochloride) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Over 8500 patients with type 2 diabetes have been treated with pioglitazone in randomized, double-blind, controlled clinical trials. This includes 2605 high-risk patients with type 2 diabetes treated with pioglitazone from the PROactive clinical trial. Over 6000 patients have been treated for 6 months or longer, and over 4500 patients for one year or longer. Over 3000 patients have received pioglitazone for at least 2 years.

The most common adverse events reported in at least 5% of patients in the controlled 16-week clinical trial between placebo plus metformin and pioglitazone 30 mg plus metformin were upper respiratory tract infection (15.6% and 15.5%), diarrhea (6.3% and 4.8%), combined edema/peripheral edema (2.5% and 6.0%) and headache (1.9% and 6.0%), respectively.

The incidence and type of adverse events reported in at least 5% of patients in any combined treatment group from the 24-week study comparing pioglitazone 30 mg plus metformin and pioglitazone 45 mg plus metformin are shown in Table 4; the rate of adverse events resulting in study discontinuation between the two treatment groups was 7.8% and 7.7%, respectively.  

Table 4. Adverse Events That Occurred in ≥ 5% of Patients in Any Treatment Group During the 24-Week Study
Adverse Event
Preferred Term
Pioglitazone 30 mg
+ metformin
N=411
n (%)
Pioglitazone 45 mg
+ metformin
N=416
n (%)
Upper Respiratory Tract Infection 51 (12.4)56 (13.5)
Diarrhea 24 (5.8)20 (4.8)
Nausea24 (5.8)15 (3.6)
Headache19 (4.6)22 (5.3)
Urinary Tract Infection 24 (5.8) 22 (5.3)
Sinusitis 18 (4.4) 21 (5.0)
Dizziness 22 (5.4) 20 (4.8)
Edema Lower Limb12 (2.9)47 (11.3)
Weight Increased12 (2.9)28 (6.7)

Most clinical adverse events were similar between groups treated with pioglitazone in combination with metformin and those treated with pioglitazone monotherapy. Other adverse events reported in at least 5% of patients in controlled clinical trials between placebo and pioglitazone monotherapy included myalgia (2.7% and 5.4%), tooth disorder (2.3% and 5.3%), diabetes mellitus aggravated (8.1% and 5.1%) and pharyngitis (0.8% and 5.1%), respectively.

In U.S. double-blind studies, anemia was reported in ≤ 2% of patients treated with pioglitazone plus metformin (see PRECAUTIONS, General: Pioglitazone hydrochloride ).

In monotherapy studies, edema was reported for 4.8% (with doses from 7.5 mg to 45 mg) of patients treated with pioglitazone versus 1.2% of placebo-treated patients. Most of these events were considered mild or moderate in intensity (see PRECAUTIONS, General: Pioglitazone hydrochloride ).

Prospective Pioglitazone Clinical Trial In Macrovascular Events (PROactive)

In PROactive, 5238 patients with type 2 diabetes and a prior history of macrovascular disease were treated with ACTOS (n=2605), force-titrated up to 45 mg daily, or placebo (n=2633), in addition to standard of care. Almost all subjects (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, ARBs, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates). Patients had a mean age of 61.8 years, mean duration of diabetes 9.5 years, and mean A1C 8.1%. Average duration of follow-up was 34.5 months. The primary objective of this trial was to examine the effect of ACTOS on mortality and macrovascular morbidity in patients with type 2 diabetes mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in the cardiovascular composite endpoint (see table 5 below). Although there was no statistically significant difference between ACTOS and placebo for the 3-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with ACTOS.

Table 5 Number of First and Total Events for Each Component within the Cardiovascular Composite Endpoint

Placebo
N=2633
ACTOS
N=2605
Cardiovascular Events First Events
(N)
Total events
(N)
First Events
(N)
Total events
(N)
Any event572900514803
All-cause mortality122186110177
Non-fatal MI118157105131
Stroke961197692
ACS63784265
Cardiac intervention (CABG/PCI)101240101195
Major leg amputation1528928
Leg revascularization579271115

Postmarketing reports of new onset or worsening diabetic macular edema with decreased visual acuity have also been received (see PRECAUTIONS, General: Pioglitazone hydrochloride ).



REPORTS OF SUSPECTED ACTOPLUS MET SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Actoplus MET. The information is not vetted and should not be considered as verified clinical evidence.

Possible Actoplus MET side effects / adverse reactions in 62 year old female

Reported by a physician from United States on 2011-10-04

Patient: 62 year old female

Reactions: Bladder Cancer

Suspect drug(s):
Actoplus MET



Possible Actoplus MET side effects / adverse reactions in 60 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-05

Patient: 60 year old male

Reactions: Bladder Cancer

Suspect drug(s):
Actoplus MET



Possible Actoplus MET side effects / adverse reactions in 60 year old male

Reported by a physician from United States on 2011-10-14

Patient: 60 year old male

Reactions: Bladder Cancer

Adverse event resulted in: hospitalization

Suspect drug(s):
Actoplus MET



See index of all Actoplus MET side effect reports >>

Drug label data at the top of this Page last updated: 2009-01-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014